Ortuzar, Natalia, Karu, Kersti, Presa, Daniela, Morais, Goreti R., Sheldrake, Helen M., Shnyder, Steve D., Barnieh, Francis M., Loadman, Paul M., Patterson, Laurence H., Pors, Klaus and Searcey, Mark (2021) Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. Bioorganic & Medicinal Chemistry, 40. ISSN 0968-0896

	PDF (Accepted_Manuscript) - Accepted Version Restricted to Repository staff only until 21 April 2022. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (490kB) | Request a copy
	PDF (Accepted_Manuscript) - Accepted Version Restricted to Repository staff only until 21 April 2022. Download (661kB) | Request a copy

Abstract

The duocarmycins belong to a class of agent which has great potential for use in cancer therapy. Their exquisite potency means they are too toxic for systemic use, and targeted approaches are required to unlock their clinical potential. In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill. We report on synthetic and biological explorations of racemic seco-CI-MI, where MI is a 5-methoxy indole motif, and dehydroxylated analogues. We show up to a 10-fold bioactivation of de-OH CI-MI and a fluoro bioprecursor analogue in CYP1A1-transfected cells. Using CYP bactosomes, we also demonstrate that CYP1A2 but not CYP1B1 or CYP3A4 has propensity for potentiating these compounds, indicating preference for CYP1A bioactivation.

Item Type:	Article
Faculty \ School:	Faculty of Science > School of Pharmacy
Related URLs:	https://linkinghub.elsevier.com/retrieve...
Depositing User:	LivePure Connector
Date Deposited:	23 Apr 2021 23:49
Last Modified:	09 Jul 2021 07:21
URI:	https://ueaeprints.uea.ac.uk/id/eprint/79866
DOI:	10.1016/j.bmc.2021.116167

Actions (login required)

View Item